Introduction
============

Chronic kidney disease (CKD) is a prevalent comorbidity among HIV-infected persons \[[@R1],[@R2]\]. It is estimated that 5--11% of people living with HIV have mild to moderately reduced kidney function \[[@R3]--[@R5]\], increasing their risk of cardiovascular disease and premature mortality \[[@R6],[@R7]\]. HIV-associated nephropathy (HIVAN), which is associated with rapid progression to end-stage renal disease (ESRD), is the classic kidney disease presentation among HIV patients, particularly in African Americans \[[@R8]\]. With the introduction of antiretroviral therapy (ART), which has been effective in the prevention and treatment of HIVAN \[[@R9],[@R10]\], the spectrum of CKD among HIV-infected persons has changed. Of late, the increasing CKD burden among HIV-infected persons has been attributed to aging, metabolic changes associated with a greater prevalence of diabetes and hypertension, and direct nephrotoxic complications from prolonged ART use \[[@R1],[@R11]\].

Hepatitis C virus (HCV) coinfection has also been implicated as an important risk factor for CKD and ESRD among HIV patients \[[@R12]--[@R16]\]. Because of shared routes of transmission, approximately 25% of people living with HIV are also coinfected with HCV \[[@R17]\]. Membranoproliferative glomerulonephritis (MPGN) is more common in HCV coinfected compared to HIV monoinfected patients \[[@R18],[@R19]\]. MPGN is associated with type II mixed cryoglobulinemia, which may represent a pathway by which HCV affects the kidney \[[@R20]\]. A recent epidemiologic study, however, found no association between HCV RNA and CKD, suggesting that the excess risk associated with HCV infection may be attributable to other exposures in this population \[[@R21]\].

Injection drug use (IDU), the primary route of HCV infection, remains a common behavior for many coinfected individuals \[[@R22]\]. Cocaine itself has been associated with rhabdomyolysis and acute kidney injury, and is a known nephropathic drug \[[@R23],[@R24]\]. However, there is little epidemiological evidence about the role that cocaine has on renal function or whether its use may explain the observed association between HCV and CKD. The aim of this study was to examine the association between injection cocaine use and chronic renal impairment (CRI) among HIV--HCV coinfected patients receiving clinical care.

Methods
=======

Study population
----------------

Data were obtained from the Canadian Co-Infection Cohort (CCC). This study has been described previously \[[@R25]\]. Briefly, after providing informed consent, all eligible participants at least 16 years of age with a confirmed HIV infection and serologic evidence of HCV exposure completed a baseline questionnaire to provide sociodemographic information and self-reported injection drug histories. Medical records were abstracted to obtain ART treatment histories, and AIDS, liver disease, and other comorbidities. Standard laboratory analyses were used to measure CD4^+^ T-cell counts, HIV viral load, and HCV viremia, using qualitative or quantitative molecular HCV RNA assays. A serum biochemistry panel was also performed, which included measurement of serum creatinine (SCr). All information was updated at bi-annual follow-up visits. The study was approved by the community advisory committee of the Canadian Institutes of Health Research (CIHR) -- Canadian HIV Trials Network -- and by all institutional ethics boards of participating centers.

We included 1366 CCC participants enrolled between January 2003 and October 2014, who had at least one SCr measurement. The first study visit with an available SCr measurement was defined as the index visit; 98% of participants had their first SCr measurement at enrollment. The study population was divided into prevalent and incident cohorts for two separate analyses (Fig. [1](#F1){ref-type="fig"}). For the prevalent cohort, we included all participants who enrolled after February 2007, the date after which study questionnaires introduced a question on injection drug histories. For the incident cohort, we included all participants without CRI (see definition below) at the index visit and who were followed for at least two study visits. No exclusion based on the older questionnaire was used for the incident cohort because questions on current injection use were available on all questionnaires.

![Study participant flow chart for prevalent and incident cohorts.](aids-30-1403-g001){#F1}

Chronic renal impairment
------------------------

Prevalent CRI was defined as an estimated glomerular filtration rate (eGFR) below 70 ml/min per 1.73 m^2^ at the index visit. For those who did not have CRI at the index visit, incident CRI was defined as two consecutive eGFR values of less than 70 ml/min per 1.73 m^2^\[[@R26]\]. We calculated eGFR using the 2009 SCr-based CKD-epidemiology (EPI) equation \[[@R27]\]. This equation has been validated in HIV-infected populations \[[@R28],[@R29]\]. A confirmed eGFR decline to less than 70 ml/min per 1.73 m^2^ was chosen to maximize study power, but it is also clinically relevant as renal interventions can be initiated to prevent kidney disease progression \[[@R30]\].

Exposure and covariate definitions
----------------------------------

For the prevalent cohort, past injection cocaine use was defined as any self-reported use prior to the index visit. For the incident cohort, current injection cocaine use was defined as any self-reported use in the past 6 months. Frequency of injection cocaine use was categorized as: no use in the past month (referent), occasional use (\<1 day/week), regular use (1 or 2 days/week), or heavy use (≥3 days/week). Cumulative exposure to injection cocaine was defined using the proportion of total follow-up time when a participant self-reported using any amount of the drug by injection. The following categories were used: no use during follow-up (referent), low (≥1% to \<33% of follow-up time), moderate (≥33% to \<75%), and high (≥75%). All injection cocaine exposures in the incident cohort analysis were time-updated.

Hepatitis C virus viremia was measured with either a qualitative (e.g. Amplicor HCV Test v2.0) or quantitative molecular HCV RNA assay (e.g. Abbott Real Time PCR) according to study center-specific laboratory standards. Any participant with detectable HCV viremia from a qualitative or quantitative assay was considered to have a chronic HCV infection.

On the basis of low-income cut-offs from Statistics Canada, annual income was dichotomized at 24 000 Canadian dollars \[[@R31]\]. Hypertension was defined by clinical diagnosis, SBP above 140 mmHg or DBP above 90 mmHg, or the use of any antihypertensive drug. Diabetes was defined by clinical diagnosis or the use of insulin or any oral hypoglycemic agents. End-stage liver disease (ESLD) was defined by any diagnosis of cirrhosis, ascites, varices, spontaneous bacterial peritonitis, portal hypertension, encephalopathy, or hepatocellular carcinoma. In the incident cohort, hypertension and ESLD were coded as time-updated ever diagnosed variables. AIDS was defined as a diagnosis of any opportunistic infection or AIDS-related illness, regardless of CD4^+^ cell count.

Statistical analysis
--------------------

### Prevalent cohort

Logistic regression was used to calculate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association between past injection cocaine use and prevalent CRI. The multivariate model was adjusted for age, sex, income, chronic HCV infection, detectable HIV viral load (\>50 copies/ml), any past tenofovir, ritonavir-boosted or unboosted atazanavir, and lopinavir use, and prevalent hypertension. Covariates were selected *a priori* based on their plausibility as confounders for the past injection cocaine and kidney disease relationship. Missing data were imputed using fully conditional specification multiple imputation (FCS-MI) \[[@R32]\]. Continuous covariates were imputed using linear regression, and dichotomous variables were imputed using logistic regression. The imputation model included all covariates in the multivariate model and an indicator for CRI. We created 10 imputed data sets and combined regression results using Rubin\'s rules \[[@R32]\].

### Incident cohort

Participants were followed from the index visit until they developed incident CRI, died, were lost to follow-up, or had their last visit prior to 1 October 2014. Person-time was censored for participants not developing CRI at their last visit. Discrete-time proportional-hazards models were used to estimate crude and adjusted hazard ratios and 95% CIs for CRI \[[@R33]\]. Three separate models were fit for current injection cocaine use, current frequency of use, and cumulative exposure to injection cocaine. All multivariate models were adjusted for age, sex, income, chronic HCV infection, CD4^+^ cell count, detectable HIV viral load, tenofovir, atazanavir and lopinavir use, AIDS diagnosis in the past 6 months, and prevalent hypertension, and ESLD, using time-updated covariates. We tested for interaction between the three injection cocaine exposures and all covariates. Missing longitudinal data were also imputed. STATA version 13.1 (College Station, Texas, USA) was used for all analyses.

### Supplemental analyses

In a supplemental analysis, we modeled continuous eGFR using generalized estimating equations (GEEs) to compare longitudinal rates of change in eGFR per year between injection cocaine users and nonusers. To examine if any observed association was related to cocaine and not the injection route of administration, we also considered the role of current and cumulative exposure to noninjection cocaine and CRI using discrete-time proportional-hazards models.

Results
=======

Prevalent cohort
----------------

Of the 1366 participants included, 1129 (83%) met the inclusion criteria (Fig. [1](#F1){ref-type="fig"}). Overall, most participants were men, aged over 45 years and who had been infected with HCV for a median of 20 years. At the index visit, 847 participants (75%) reported a history of injection cocaine use and 937 (83%) had a chronic HCV infection. Of those without evidence of HCV viremia, 100 (59%) had spontaneously cleared their infection and 63 (41%) had cleared following prior HCV treatment. Participant characteristics with and without a history of injection cocaine use are shown in Table [1](#T1){ref-type="table"}. Compared to participants who did not inject cocaine, those who had a history of use were younger, were more likely to be women, have low income, have been smokers, currently have a detectable HIV viral load, and have used an atazanavir-containing ART regimen.

In univariate analysis, past injection cocaine use was associated with a significantly increased risk of CRI among HIV--HCV coinfected patients (Table [2](#T2){ref-type="table"}). After adjustment, past injection cocaine use increased the risk of CRI, but was no longer significant. Presence of HCV viremia was not associated with CRI in either univariate or multivariate models. Increasing age, female sex, past tenofovir, lopinavir, and atazanavir use were also associated with CRI in the multivariate analysis. Results for injection cocaine use were qualitatively similar when the model was further adjusted for smoking, nadir CD4^+^ cell count, AIDS, diabetes, and ESLD (OR 2.06, 95% CI 0.96, 4.43), and when eGFR below 60 ml/min per 1.73 m^2^ was used to define prevalent CRI (OR 1.92, 95% CI 0.75, 4.91).

Incident cohort
---------------

Among the 1366 participants with available eGFR measurements, 1061 (78%) did not have prevalent CRI at the index visit and were followed for at least two study visits (Fig. [1](#F1){ref-type="fig"}). During follow-up, 126 participants (12%) developed incident CRI and the remaining 935 were censored without having the event. Of those who did not develop CRI, 678 were administratively censored, 94 died, 87 were lost-to-follow-up, and 76 withdrew from the study. Overall, the median duration of follow-up was 3.6 years \[interquartile range (IQR) 1.6, 5.5\] and the crude CRI incidence rate was 31 per 1000 person-years of follow-up (95% CI 26, 37). The median eGFR of those at the time of CRI was 63 ml/min per 1.73 m^2^ (IQR 57, 67). The majority of patients with CRI (89%) never recovered eGFR above 70 ml/min per 1.73 m^2^ and 42% progressed to eGFR below 60 ml/min per 1.73 m^2^.

Participant characteristics at the index visit and at the end of follow-up stratified by whether they developed CRI are summarized in Table [3](#T3){ref-type="table"}. Overall, most participants had initially healthy kidney function, with a median eGFR of 104 ml/min per 1.73 m^2^ (IQR 94, 112). Two hundred and eighty-seven participants (27%) reported recent injection cocaine use in the past 6 months prior to the index visit. Of these, 61 participants (21%) reported using injection cocaine on average of at least 3 days/week. Four hundred and twenty participants (40%) reported using injection cocaine at least once during follow-up. Compared to those participants who did not develop CRI, those with CRI were older, more likely to be women, had a lower income and CD4^+^ cell count, were more likely to be on atazanavir or lopinavir-based regimens, and were more likely to have hypertension and ESLD.

The discrete-time proportional-hazards models are shown in Table [4](#T4){ref-type="table"}. After adjusting for time-updated confounders, current injection cocaine use increased the risk of CRI by 26%, though this effect was highly variable. Those who reported recently using injecting cocaine at least 3 days/week, however, had a more than two-fold greater risk of developing CRI, compared to those who did not report using injection cocaine since the last visit. Those who regularly reported using injection cocaine (i.e. ≥75% of follow-up visits) were also at greater risk of developing CRI, compared to those who never reported using the drug. In all adjusted models, increasing age, female sex, atazanavir use, incident AIDS diagnosis, and prevalent ESLD were associated with CRI. As with the prevalent analysis, chronic HCV was not associated with incident CRI. There was no evidence of interaction between any of the injection cocaine exposures and other covariates in all models (all *P* \> 0.05). Further adjustment for smoking, diabetes, and time since HCV infection did not appreciably change the results.

Supplemental analyses
---------------------

First, we compared annual rates of change in eGFR between injection cocaine users and nonusers using a longitudinal model (Suppl Table 1). The overall annual rate of change in eGFR was 1.1 ml/min per 1.73 m^2^. Relative to nonusers, current injection cocaine users experienced a decline in eGFR that was 0.27 ml/min per 1.73 m^2^ per year faster (95% CI −0.01, 0.55). Heavy users and those who regularly reported using injection cocaine experienced declines that were 0.49 ml/min per 1.73 m^2^ per year (95% CI −0.07, 1.06) and 0.48 ml/min per 1.73 m^2^ per year faster (95% CI 0.11, 0.86), respectively, compared to nonusers. Second, we compared the association between cocaine used through noninjection routes of administration and CRI. Current and cumulative exposure to noninjection cocaine demonstrated a similar association with CRI as injection cocaine (Suppl Table 2). Current users of noninjection crack/cocaine had a 54% greater risk of CRI (hazard ratio 1.54, 95% CI 0.98, 2.41) and heavy users had a two-fold greater risk of CRI (hazard ratio 2.03, 95% CI 1.22, 3.39).

Discussion
==========

In this prospective study of HIV--HCV coinfected patients, past injection cocaine increased the risk of CRI, independent of chronic HCV infection, ART use, and other traditional kidney disease risk factors. Furthermore, frequent injection cocaine use of three or more times per week was associated with rapid progression to CRI. We also found that regular use of injection cocaine was associated with CRI progression. Relative effect estimates for cocaine use in this analysis were large. For example, past injection cocaine use was associated with an approximately two-fold greater risk of prevalent CRI. Similar associations were also observed for frequent and cumulative injection and noninjection cocaine in the incident cohort. We also found important clinical differences in annual rates of change in eGFR between injection cocaine users and nonusers. Given that the prevalence of injection drug use in this population is high, cocaine use may be an important modifiable risk factor for CKD among coinfected patients \[[@R22]\]. These results support that screening guidelines for CKD among HIV-infected populations should be expanded to include cocaine users as a high-risk group for kidney disease, as has previously been suggested \[[@R34],[@R35]\].

This is the first cohort study to examine the effect of injection cocaine use, a known nephropathic drug \[[@R23],[@R24],[@R36]\], on renal function among HIV or coinfected populations. Previous research in non-HIV-infected populations has been limited by small sample sizes, poor exposure ascertainment, and the use of nonlongitudinal study designs, which have led to inconsistent results. For example, in a case-control study of recreational drug use and ESRD, cocaine use was not associated with being on dialysis; however, the effect estimate lacked precision as the population controls reported no past illicit drug use \[[@R37]\]. In a cohort of 647 hypertensive men, past cocaine use was strongly associated with mild increases in SCr concentrations \[[@R38]\]. However, because of the retrospective cohort design, drug use may have occurred after follow-up time in the analysis began for many participants. Results from this study are similar to results from a longitudinal analysis of acute kidney disease among a cohort of 367 HCV-infected patients, which have characteristics comparable to our coinfected cohort \[[@R39]\]. Garg *et al.*\[[@R39]\] reported that recent injection or noninjection cocaine use was associated with a two-fold greater risk of a concomitant rise in SCr, which may be a marker for future chronic disease. Our study supports that elevations in creatinine associated with cocaine use are not transient, but rather lead to chronic kidney dysfunction because the vast majority of those developing CRI never returned to normal renal function.

Results from this study are consistent with clinical studies that demonstrate pathogenic effects of cocaine on the kidney \[[@R40]\]. Cocaine is known to have strong vasoconstrictive effects on smooth muscle tissue, which may accelerate hypertensive nephrosclerosis. Furthermore, kidney epithelial cells exposed to cocaine experienced a reduction in intracellular glutathione, an antioxidant and important component of cellular homeostasis, increasing oxidative stress, and may reduce normal kidney function \[[@R24]\]. Results of our analysis were appreciably similar for noninjection cocaine use, suggesting the nephropathic potential of cocaine is drug-specific and not related to route of administration.

It is notable that in our analysis, chronic HCV infection was not associated with an increased risk of CRI. As HCV has been associated with specific glomerular diseases, such as MPGN, it has been hypothesized that patients with a chronic HCV infection may be at a greater risk for CKD, compared to those who have spontaneously cleared the virus or developed a sustained virologic response to HCV treatment \[[@R41]\]. Indeed, in studies of patients enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) and Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) trials, and the EuroSIDA cohort, the coinfected patients with HCV viral loads at least 800 000 and 500 000 IU/ml, respectively, had larger CKD incidence rates compared to those with resolved HCV infections \[[@R42],[@R43]\]. In the larger North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) cohort, however, rates of incident CKD did not differ between coinfected patients with any quantifiable or undetectable HCV viral load \[[@R21]\]. None of these studies accounted for cocaine use. It is therefore possible that some or much of the effect attributed to HCV may instead be related to cocaine abuse rather than to HCV itself. Due to the lack of quantitative measures for all participants, we were unable to determine if HCV RNA levels may impact risk of renal impairment at higher thresholds. Among the subset of participants with available quantitative HCV RNA measures, the median HCV RNA was high (median 1.3 million IU/ml) and there was no evidence that cocaine use was associated with level of HCV RNA, suggesting our findings were not confounded by HCV viremia.

As reported previously, past exposure to tenofovir was associated with prevalent CRI \[[@R13],[@R44]\]. Consistent with findings from an assessment of the effect of cumulative ART exposure, past use of lopinavir and atazanavir, two protease inhibitors, and current atazanavir use were also associated with CRI in this study \[[@R26]\]. We found no evidence of interaction between any of these nephrotoxic ART agents and injection cocaine use, suggesting that renal safety of these medications is not affected by cocaine use.

The study has several important strengths. First, the cohort collected detailed, time-updated information on the use of specific illicit drugs, and their frequency of use. This information is typically not recorded in clinical databases used for other HIV cohort studies on CKD. Previous studies have also ascertained drug exposure retrospectively or at only one time point. Second, with regular HCV RNA testing, this study isolated the effect of HCV viremia from the effect of specific injection drug use, which has not previously been done in HIV-infected cohorts. Finally, we used a validated kidney function equation to measure eGFR and required two consecutive measurements, at least 3 months apart, to confirm incident CRI and rule out acute kidney injury.

Our study has also several potential limitations. First, although data were obtained from a large cohort of coinfected patients, study power was limited to detect smaller effect sizes and interactions between exposure and covariates. Therefore, we only considered CRI as our outcome rather than traditional CKD (eGFR \<60 ml/min per 1.73 m^2^), as there were few CKD events. Whereas it is possible that risk factors for CRI may differ from CKD, there is increasing interest in identifying patients at earlier risk for CKD, so interventions and modifications of treatment can be implemented \[[@R26]\]. Our analysis of CRI may help to achieve this aim. Second, drug history was measured by self-report and may result in misclassification if some patients failed to report drug use. We do not expect the degree of misclassification to be biased, however, as drug use history was collected independently of objective serum creatinine measures. Third, as only 3% of the study participants were black, we were unable to adequately evaluate race as a confounder or effect modifier. Finally, HCV viremia was measured using a combination of qualitative and quantitative molecular assays. As a result, we were unable to assess a dose--response relationship between viremia and CRI as we classified all those with any detectable HCV viral load as being viremic.

In conclusion, we found evidence to suggest that cumulative exposure and frequent cocaine use are associated with CRI progression among HIV--HCV coinfected patients. The role of substance use in contributing to renal disease in coinfection has been underappreciated and should be taken into consideration when evaluating impaired renal function in this setting.
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###### 

Baseline characteristics of 1129 Canadian Co-Infection Cohort participants by history of injection cocaine use^a^.

  Characteristics[^b^](#TF1-2){ref-type="table-fn"}   History of injection cocaine use (n = 847)   No history of injection cocaine use (n = 277)
  --------------------------------------------------- -------------------------------------------- -----------------------------------------------
  Median age, years (IQR)                             45 (39, 50)                                  47 (41, 53)
  Women                                               276 (33%)                                    48 (17%)
  Income ≤\$24 000/year                               765 (90%)                                    172 (62%)
  Ever smoker                                         815 (96%)                                    204 (74%)
  Current alcohol consumption                         419 (49%)                                    173 (62%)
  Other injection drug use history                    617 (73%)                                    26 (9%)
  Chronic HCV infection                               698 (82%)                                    237 (86%)
  Median time since HCV infection, years (IQR)        21 (13, 29)                                  8 (2, 17)
  Median current CD4^+^ cell count, cells/μl (IQR)    394 (250, 577)                               450 (293, 620)
  Median nadir CD4^+^ cell count, cells/μl (IQR)      170 (80, 299)                                184 (70, 300)
  Current ART use                                     692 (82%)                                    250 (90%)
  Detectable HIV viral load \>50 copies/ml            315 (37%)                                    68 (25%)
  Tenofovir use                                       505 (60%)                                    167 (60%)
  Atazanavir use                                      354 (42%)                                    72 (26%)
  Lopinavir use                                       273 (32%)                                    104 (38%)
  Clinical AIDS diagnosis                             226 (27%)                                    80 (29%)
  Hypertension                                        112 (13%)                                    50 (18%)
  Diabetes                                            36 (4%)                                      12 (4%)
  End-stage liver disease                             67 (8%)                                      29 (10%)

Values are *n* (%), unless otherwise indicated.

ART, antiretroviral therapy; HCV, hepatitis C virus; IQR, interquartile range.

^a^Five participants were missing data on injection cocaine use history.

^b^Missing data was as follows: income (*n* = 1); smoking (*n* = 2); chronic HCV (*n* = 37); nadir CD4^+^ cell count (*n* = 67); HIV viral load (*n* = 21); hypertension (*n* = 6); diabetes (*n* = 6); and clinical AIDS diagnosis (*n* = 5).

###### 

Crude and adjusted odds ratios for prevalent chronic renal impairment (*N* = 1129).

                                                   Unadjusted OR (95% CI) [^a^](#TF2-1){ref-type="table-fn"}   Adjusted OR (95% CI)[^a^](#TF2-1){ref-type="table-fn"}
  ------------------------------------------------ ----------------------------------------------------------- --------------------------------------------------------
  Past injection cocaine use                       1.91 (1.04, 3.51)                                           2.03 (0.96, 4.32)
  Chronic HCV infection                            0.90 (0.48, 1.67)                                           1.05 (0.54, 2.06)
  Age (per 5-year increase)                        1.46 (1.28, 1.66)                                           1.69 (1.43, 1.99)
  Women                                            2.77 (1.78, 4.31)                                           4.51 (2.70, 7.54)
  Current income ≤\$24 000/year                    2.04 (0.97, 4.29)                                           1.56 (0.69, 3.52)
  Time since HCV infection (per 5-year increase)   1.21 (1.10, 1.34)                                           1.03 (0.91, 1.16)
  Detectable HIV viral load (\>50 copies/ml)       0.81 (0.50, 1.31)                                           1.02 (0.60, 1.74)
  Tenofovir use                                    2.10 (1.28, 3.46)                                           1.97 (1.13, 3.42)
  Atazanavir use                                   2.01 (1.30, 3.13)                                           1.90 (1.17, 3.09)
  Lopinavir use                                    1.96 (1.26, 3.05)                                           1.91 (1.17, 3.12)
  Hypertension                                     2.04 (1.21, 3.45)                                           1.66 (0.92, 2.99)

CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio.

^a^Multiple imputation used for missing data.

###### 

Baseline participant characteristics and characteristics at end of follow-up by chronic renal impairment outcome in the incident cohort (*N* = 1061).

  Characteristics                            Index visit[^a^](#TF3-1){ref-type="table-fn"}   Status at end of follow-up[^b^](#TF3-2){ref-type="table-fn"}   
  ------------------------------------------ ----------------------------------------------- -------------------------------------------------------------- ----------------
  Median age, years (IQR)                    45 (39, 50)                                     51 (46, 57)                                                    48 (43, 53)
  Female                                     266 (25%)                                       37 (29%)                                                       229 (24%)
  Income ≤\$24 000/year                      873 (82%)                                       107 (87%)                                                      748 (81%)
  Current smoker                             781 (74%)                                       91 (72%)                                                       663 (72%)
  Current injection cocaine use              287 (27%)                                       26 (21%)                                                       172 (19%)
  Median eGFR, ml/min per 1.73 m^2^ (IQR)    104 (94, 112)                                   63 (57, 67)                                                    101 (91, 110)
  Chronic HCV infection                      886 (84%)                                       90 (73%)                                                       649 (70%)
  Median CD4^+^ cell count, cells/μl (IQR)   400 (257, 574)                                  417 (230, 640)                                                 478 (296, 664)
  Detectable HIV viral load \>50 copies/ml   393 (37%)                                       24 (20%)                                                       214 (23%)
  Tenofovir use                              438 (41%)                                       68 (54%)                                                       500 (53%)
  Atazanavir use                             253 (24%)                                       40 (32%)                                                       226 (24%)
  Lopinavir use                              184 (17%)                                       23 (18%)                                                       118 (13%)
  AIDS diagnosis                             283 (27%)                                       47 (37%)                                                       287 (31%)
  Hypertension                               104 (10%)                                       34 (27%)                                                       170 (18%)
  Diabetes                                   43 (4%)                                         11 (9%)                                                        52 (6%)
  End-stage liver disease                    88 (8%)                                         32 (25%)                                                       150 (16%)

Values are *n* (%), unless otherwise indicated.

CRI, chronic renal impairment; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; IQR, interquartile range.

^a^Missing data at the index visit was as follows: income (*n* = 6); current smoking (*n* = 6); injection cocaine (*n* = 3); chronic HCV (*n* = 29); CD4^+^ cell count (*n* = 7); HIV viral load (*n* = 10); and clinical AIDS diagnosis (*n* = 6).

^b^Missing data at the end of follow-up was as follows: income (*n* = 12); current smoking (*n* = 10); injection cocaine (*n* = 8); chronic HCV (*n* = 9); CD4^+^ cell count (*n* = 27); HIV viral load (*n* = 30); and clinical AIDS diagnosis (*n* = 23).

###### 

Discrete-time proportional-hazards analysis for incident chronic renal impairment (*N* = 1061)^a^.

  Variables                                       Unadjusted HR (95% CI)   Adjusted HR (95% CI)                       
  ----------------------------------------------- ------------------------ ---------------------- ------------------- -------------------
  Current injection cocaine use                   0.96 (0.62, 1.48)        1.26 (0.80, 2.00)      --^\*^              --^\*^
  Frequency of use                                                                                                    
   Nonuser                                        1 (Reference)            --^\*^                 1 (Reference)       --^\*^
   Occasional                                     0.67 (0.36, 1.25)        --^\*^                 0.83 (0.44, 1.58)   --^\*^
   Regular                                        1.22 (0.50, 3.00)        --^\*^                 1.73 (0.69, 4.34)   --^\*^
   Heavy                                          1.74 (0.91, 3.34)        --^\*^                 2.65 (1.35, 5.21)   --^\*^
  Proportion of follow-up time                                                                                        
   Nonuser                                        1 (Reference)            --^\*^                 --^\*^              1 (Reference)
   ≥1% to \<33%                                   0.66 (0.38, 1.13)        --^\*^                 --^\*^              0.73 (0.41, 1.28)
   ≥33% to \<75%                                  0.76 (0.43, 1.35)        --^\*^                 --^\*^              1.05 (0.57, 1.94)
   ≥75%                                           1.33 (0.82, 2.14)        --^\*^                 --^\*^              1.82 (1.07, 3.07)
  Chronic HCV infection                           1.06 (0.72, 1.58)        0.93 (0.62, 1.40)      0.94 (0.62, 1.40)   0.93 (0.62, 1.39)
  Age (per 5-year increase)                       1.49 (1.33, 1.66)        1.53 (1.36, 1.72)      1.54 (1.37, 1.74)   1.53 (1.36, 1.72)
  Women                                           1.34 (0.91, 1.97)        1.75 (1.17, 2.62)      1.75 (1.17, 2.62)   1.79 (1.19, 2.70)
  Income ≤\$24 000/year                           1.35 (0.80, 2.27)        1.65 (0.95, 2.87)      1.67 (0.96, 2.89)   1.63 (0.93, 2.86)
  CD4^+^ cell count (per 100 cells/μl increase)   0.98 (0.92, 1.04)        0.99 (0.93, 1.06)      0.99 (0.93, 1.06)   0.99 (0.93, 1.05)
  Detectable HIV viral load \>50 copies/ml        0.82 (0.52, 1.30)        0.80 (0.50, 1.29)      0.80 (0.50, 1.29)   0.77 (0.48, 1.25)
  Tenofovir use                                   1.12 (0.78, 1.59)        1.24 (0.87, 1.79)      1.24 (0.86, 1.78)   1.25 (0.87, 1.80)
  Atazanavir use                                  1.30 (0.89, 1.89)        1.51 (1.01, 2.26)      1.53 (1.02, 2.29)   1.51 (1.01, 2.27)
  Lopinavir use                                   1.03 (0.65, 1.62)        1.25 (0.77, 2.03)      1.22 (0.75, 1.99)   1.23 (0.75, 2.00)
  Incident AIDS diagnosis                         2.71 (1.19, 6.18)        3.21 (1.38, 7.45)      3.31 (1.43, 7.70)   3.44 (1.48, 8.03)
  Hypertension                                    1.79 (1.20, 2.67)        1.31 (0.86, 1.99)      1.29 (0.85, 1.96)   1.32 (0.87, 2.00)
  End-stage liver disease                         2.54 (1.70, 3.80)        2.10 (1.37, 3.22)      2.10 (1.38, 3.22)   2.11 (1.37, 3.23)

The symbol '--' indicates that the covariate excluded from multivariate model.

CI, confidence interval; HCV, hepatitis C virus; HR, hazard ratio.

^a^Multiple imputation used for missing data.
